Oragenics, Inc. (OGEN) announced on Monday that its flagship drug candidate, ONP-002, intended for the treatment of concussions, has passed an in vivo study aimed at assessing the potential for DNA damage and cancer risk from multi-day treatments. As a result, the company's shares gained over 6% in pre-market trading, reaching $1.49.
A concussion is classified as a mild traumatic brain injury that impacts brain functionality.
The findings from the in vivo study indicated that multi-day treatment for concussions with ONP-002 does not induce genotoxicity. Consequently, Oragenics plans to advance to a Phase 2 study involving concussed patients using ONP-002.
Oragenics' stock previously closed at $1.40 on Friday, representing a 29.63% increase. Over the past year, the stock has fluctuated between $0.86 and $7.74.
